Trabectedin for the treatment of breast cancer

Maurizio Dincalci, Alberto Zambelli

Research output: Contribution to journalArticle

Abstract

Introduction: Trabectedin is an anti-tumor compound registered in Europe and in several other countries, for the second-line treatment of soft tissue sarcoma (STS) and for ovarian cancer in combination with liposomal doxorubicin. Trabectedin inhibits cancer cell proliferation mainly affecting the transcription regulation. Trabectedin also acts as a modulator of tumor microenvironment by reducing the number of tumor associated macrophages (TAM). Because of its unique mechanism of action, trabectedin has the potential to act as antineoplastic agent also in several solid malignancies, including breast cancer (BC).Areas covered: This article reviews the preclinical and clinical data of trabectedin focusing on development in metastatic BC (mBC). Comments regarding the nature and the results of these trials are included.Expert opinion: Trabectedin is thought to have a crucial activity with defective DNA-repair machinery and also in modulating the tumor micro-environment and the immune-system of cancer patients. From the current available data, we recognize a potential activity of trabectedin in mBC and support the renewed efforts to better elucidate the value of trabectedin in this indication.

Original languageEnglish
Pages (from-to)105-115
Number of pages11
JournalExpert Opinion on Investigational Drugs
Volume25
Issue number1
DOIs
Publication statusPublished - Jan 2 2016

Fingerprint

trabectedin
Breast Neoplasms
Neoplasms
Therapeutics
Tumor Microenvironment
Expert Testimony

Keywords

  • BRCA mutation
  • DNA repair
  • metastatic breast cancer
  • trabectedin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Trabectedin for the treatment of breast cancer. / Dincalci, Maurizio; Zambelli, Alberto.

In: Expert Opinion on Investigational Drugs, Vol. 25, No. 1, 02.01.2016, p. 105-115.

Research output: Contribution to journalArticle

@article{b4e5b350cbf94bfeaed3af9149aa7902,
title = "Trabectedin for the treatment of breast cancer",
abstract = "Introduction: Trabectedin is an anti-tumor compound registered in Europe and in several other countries, for the second-line treatment of soft tissue sarcoma (STS) and for ovarian cancer in combination with liposomal doxorubicin. Trabectedin inhibits cancer cell proliferation mainly affecting the transcription regulation. Trabectedin also acts as a modulator of tumor microenvironment by reducing the number of tumor associated macrophages (TAM). Because of its unique mechanism of action, trabectedin has the potential to act as antineoplastic agent also in several solid malignancies, including breast cancer (BC).Areas covered: This article reviews the preclinical and clinical data of trabectedin focusing on development in metastatic BC (mBC). Comments regarding the nature and the results of these trials are included.Expert opinion: Trabectedin is thought to have a crucial activity with defective DNA-repair machinery and also in modulating the tumor micro-environment and the immune-system of cancer patients. From the current available data, we recognize a potential activity of trabectedin in mBC and support the renewed efforts to better elucidate the value of trabectedin in this indication.",
keywords = "BRCA mutation, DNA repair, metastatic breast cancer, trabectedin",
author = "Maurizio Dincalci and Alberto Zambelli",
year = "2016",
month = "1",
day = "2",
doi = "10.1517/13543784.2016.1124086",
language = "English",
volume = "25",
pages = "105--115",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Trabectedin for the treatment of breast cancer

AU - Dincalci, Maurizio

AU - Zambelli, Alberto

PY - 2016/1/2

Y1 - 2016/1/2

N2 - Introduction: Trabectedin is an anti-tumor compound registered in Europe and in several other countries, for the second-line treatment of soft tissue sarcoma (STS) and for ovarian cancer in combination with liposomal doxorubicin. Trabectedin inhibits cancer cell proliferation mainly affecting the transcription regulation. Trabectedin also acts as a modulator of tumor microenvironment by reducing the number of tumor associated macrophages (TAM). Because of its unique mechanism of action, trabectedin has the potential to act as antineoplastic agent also in several solid malignancies, including breast cancer (BC).Areas covered: This article reviews the preclinical and clinical data of trabectedin focusing on development in metastatic BC (mBC). Comments regarding the nature and the results of these trials are included.Expert opinion: Trabectedin is thought to have a crucial activity with defective DNA-repair machinery and also in modulating the tumor micro-environment and the immune-system of cancer patients. From the current available data, we recognize a potential activity of trabectedin in mBC and support the renewed efforts to better elucidate the value of trabectedin in this indication.

AB - Introduction: Trabectedin is an anti-tumor compound registered in Europe and in several other countries, for the second-line treatment of soft tissue sarcoma (STS) and for ovarian cancer in combination with liposomal doxorubicin. Trabectedin inhibits cancer cell proliferation mainly affecting the transcription regulation. Trabectedin also acts as a modulator of tumor microenvironment by reducing the number of tumor associated macrophages (TAM). Because of its unique mechanism of action, trabectedin has the potential to act as antineoplastic agent also in several solid malignancies, including breast cancer (BC).Areas covered: This article reviews the preclinical and clinical data of trabectedin focusing on development in metastatic BC (mBC). Comments regarding the nature and the results of these trials are included.Expert opinion: Trabectedin is thought to have a crucial activity with defective DNA-repair machinery and also in modulating the tumor micro-environment and the immune-system of cancer patients. From the current available data, we recognize a potential activity of trabectedin in mBC and support the renewed efforts to better elucidate the value of trabectedin in this indication.

KW - BRCA mutation

KW - DNA repair

KW - metastatic breast cancer

KW - trabectedin

UR - http://www.scopus.com/inward/record.url?scp=84954386070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954386070&partnerID=8YFLogxK

U2 - 10.1517/13543784.2016.1124086

DO - 10.1517/13543784.2016.1124086

M3 - Article

C2 - 26592307

AN - SCOPUS:84954386070

VL - 25

SP - 105

EP - 115

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 1

ER -